Amgen is standing behind a uncommon illness drug that the FDA needs off the market on account of security issues and alleged scientific trial manipulation, and its protection will embrace a brand new evaluation of the pivotal information that supported the product’s preliminary approval 5 years in the past.
The pharmaceutical firm disclosed the unbiased evaluate in a letter to the FDA requesting a listening to concerning the company’s proposal to withdraw approval of the drug, Tavneos. The Amgen letter was dated June 1, the FDA’s deadline for Amgen to request a listening to. The FDA made the letter public on Thursday.
Tavneos was initially developed by ChemoCentryx, which Amgen acquired for $3.7 billion in 2022. This oral small molecule is designed to inhibit the C5a receptor of the complement system, part of the immune system. Tavneos is one in every of a restricted variety of remedies for antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, a bunch of inflammatory issues that causes irritation resulting in blood vessel and organ harm, significantly to the kidneys. However the FDA grew to become more and more involved that the drug can harm the liver.
Liver toxicity is a recognized danger of Tavneos that has been on its label since its 2021 approval, however within the warnings and precautions part and never in a extra stringent black field warning. Questions concerning the drug’s scientific trial integrity got here to the FDA’s consideration final yr from securities fraud litigation in opposition to ChemoCentryx. Within the FDA’s discover proposing withdrawal of Tavneos’s approval, the company mentioned an skilled report filed with the courtroom in that case mentioned statistical evaluation of Tavneos’s pivotal research discovered that the therapy group didn’t meet the primary trial purpose. The report added that ChemoCentryx personnel picked 9 trial individuals for readjudication, together with 5 whose scientific outcomes have been modified from “not in sustained remission” to “sustained remission.” The FDA mentioned ChemoCentryx submitted Tavneos’s new drug software with out disclosing these adjustments.
Final July, the FDA requested Amgen to reply. In line with the company, the corporate’s response confirmed key factual allegations within the courtroom report. Amgen additionally contended that the info in Tavneos’s submission have been correct and the readjudications have been applicable. The FDA disagrees.
“The Division Director didn’t know that the info on which he was relying have been unfaithful — that absent manipulation, the research outcomes weren’t statistically vital on the prevalence evaluation at week 52, and the procedures in place to make sure trial high quality have been violated,” the FDA mentioned in its proposal. “Had the Division Director recognized these info, he wouldn’t have advisable approval.”
In February, Amgen disclosed that the FDA requested Amgen to voluntarily withdraw Tavneos from the U.S. market, citing security issues and readjudicated trial information. Amgen mentioned it was assured within the risk-benefit profile for its drug and would hold promoting it. The FDA raised the stakes in late March, issuing a security alert to sufferers and clinicians about instances of significant liver damage, some deadly, related to Tavneos. Most of those instances have been in Japan. The FDA described these issues as a brand new security concern. On April 27, the FDA’s Heart for Drug Analysis and Analysis issued a proposal to withdraw Tavneos’s approval.
FDA procedures allow a drug firm to request a listening to on a drug withdrawal proposal, which Amgen did with its June 1 letter. Tavneos will stay obtainable to sufferers whereas the method continues. The contract analysis group (CRO) that dealt with Tavneos’s Part 3 scientific trial was Medpace. The unbiased trial evaluation commissioned by Amgen will come from the Duke Medical Analysis Institute (DCRI), part of the Duke College College of Drugs that operates as a full-service CRO.
The DCRI evaluation and all different supporting paperwork in help of Amgen’s listening to request are due by June 29. That’s additionally the deadline for public feedback. Lots of them submitted to this point are from individuals who say they’re sufferers who’ve benefited from Tavneos. Clinicians have additionally commented in help of Tavneos, some saying that given the restricted therapy choices for ANCA-associated vasculitis, the drug ought to stay obtainable till extra definitive info is thought concerning the liver damage danger.
Tavneos is just not but a giant income driver for Amgen, however gross sales are rising. The corporate reported $459 million in international Tavneos income for 2025, a 62% enhance from the prior yr. Whereas ChemoCentryx had projected Tavneos as having potential functions in a variety of inflammatory issues, the one scientific program for the drug listed in Amgen’s pipeline is an ongoing Part 3 trial that might help increasing the present approval to youngsters.
In early June, Amgen issued an announcement to clinicians about Tavneos stating it stays assured within the total benefit-risk profile of the drug primarily based on the scientific information, post-marketing security surveillance, and actual world proof from greater than 8,000 handled sufferers.
“Collectively, the proof demonstrates the impression of Tavneos on supporting remission, decreasing relapse danger, and enhancing kidney operate and high quality of life measures, all whereas decreasing glucocorticoid publicity and related toxicity,” the corporate mentioned.
Picture: Patrick T. Fallon/Bloomberg, by way of Getty Pictures
